UPCOMING SESSIONS in ET
Tue, Sep 8, 2026
5:00 – 6:00 AM Bangkok
Your First Mayo Clinic Evaluation: What to Expect and How to Prepare Cecelia Hernandez Click Here To Register
UPCOMING SESSIONS in ET
Tue, Sep 8, 2026 · 5:00 – 6:00 AM Bangkok
Your First Mayo Clinic Evaluation: What to Expect and How to Prepare
Cecelia Hernandez
Click Here To Register
View all sessions

News

pfizer_logo.jpg
U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL(R) (tafamidis meglumine) and VYNDAMAX(tm) (tafamidis) for…
Read more
Healthwell-Foundation-Logo.jpeg
HealthWell Foundation Opens New Amyloidosis Fund to Assist Patients With Treatment Costs
The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has launched a new fund to provide…
Read more
Vaishali-Sanchorawala.jpg
New, More Accessible Staging System Developed to Predict Survival for Patients With Light Chain Amyloidosis
A new staging system developed with a more accessible test to predict the chance of survival in patients living with light chain (AL) amyloidosis. Led by…
Read more
moleculestha.jpg
Molecules That Curb Errant Proteins of AL Amyloidosis Point to New Type of Therapy
Scientists at Scripps Research have identified a group of small molecules that prevent structural changes to proteins that are at the root of AL amyloidosis, a…
Read more
Generic_inotersen.jpg
Tegsedi™ to be Available on the NHS for hATTR Amyloidosis
Akcea Therapeutics UK Ltd., has announced that NICE has issued a positive Final Evaluation Document (FED) for Tegsedi(tm) (inotersen) for the treatment of stage 1…
Read more
prothena_logo.jpg
Prothena Reports Results From the Phase 3 VITAL Amyloidosis Study of NEOD001 (Birtamimab) in AL Amyloidosis
Prothena Corporation PLC, a clinical-stage neuroscience company, today reported final results from the Phase 3 VITAL Amyloidosis study of NEOD001 (birtamimab) in…
Read more
Martha-Gulati.jpg
ESC: Tafamidis Cuts Deaths, Admissions in TTR Cardiac Amyloidosis
Treatment with the investigational drug tafamidis was associated with a reduction in all-cause mortality and cardiovascular hospitalizations in patients with…
Read more
alnylam_logo.png
FDA Approves Alnylam’s Onpattro for Polyneuropathy of hATTR Amyloidosis
The FDA today granted Alnylam Pharmaceuticals approval for a first-in-class small interfering ribonucleic acid (siRNA) treatment-the first therapy indicated for…
Read more
Inotersen-Tegsedi.jpg
FDA OKs Inotersen (Tegsedi) for Hereditary ATTR With Polyneuropathy
The US Food and Drug Administration (FDA) has approved inotersen (Tegsedi, Akcea Therapeutics and Ionis Pharmaceuticals) for the treatment of polyneuropathy (PN) in…
Read more
Subscribe to